ArticleFrontiers in microbiology2025
Multidrug resistance of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Correlation between the expression of the lasR quorum‑sensing gene, biofilm‑related genes, and exotoxin A in Pseudomonas aeruginosa isolates: a Rep-PCR-based fingerprinting analysis.Molecular biology reports · 2026Article
- Biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa in cheese production systems.Scientific reports · 2026Article
- Genomic variants distinguish Pseudomonas aeruginosa from cystic fibrosis sputum and bloodstream infection.BMC infectious diseases · 2026Article
- Antimicrobial Resistance of Non-Fermenting Gram-Negative Bacilli in a Multidisciplinary Hospital in Romania.Biomedicines · 2025Article
- Mechanisms of antimicrobial resistance: From genetic evolution to clinical manifestations.AIMS microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with nosocomial infections are at risk of multidrug-resistant (MDR) Methods: One hundred and eight clinical isolates of Results: The susceptibility rate among the isolates was 70-75% for aminoglycosides (amikacin, gentamicin, netilmicin), 15-20% for cephalosporins (ceftazidime, ceftriaxone), 30-35% for quinolones (ciprofloxacin, levofloxacin), 10-15% for tetracyclines (tigecycline, doxycycline), 15-20% for carbapenem (meropenem), 10-15% for sulfonamide (co-trimoxazole), 5-10% for amoxiclav, and 30-35% for piperacillin/tazobactam. A total of 74.1% of the strains carried metallo- Discussion: Only the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.